Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer
Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.
Lucy Gilbert, MD, MSc, professor, Departments of Obstetrics and Gynecology, and Oncology, McGill University, director, Gynecologic Oncology and Women’s Health Research Unit, McGill University Health Center, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab (Avastin) in patients with platinum-agnostic ovarian cancer.
Upon recurrence, patients with ovarian cancer are defined as platinum-sensitive or platinum-resistant, Gilbert explains. Single-agent mirvetuximab soravtansine demonstrated effectiveness in platinum-resistant patients.
Patients with platinum-sensitive disease are eligible to receive platinum chemotherapy; however, response rates are low with platinum alone, says Gilbert.
As such, utilizing the combination of mirvetuximab soravtansine and bevacizumab may be effective in patients with ovarian cancer who are eligible for a non-platinum–based doublet, concludes Gilbert.
